REVB שווי כולל של נכסי החברה Revelation Biosciences Inc

Revelation Biosciences (REVB) operates within the biotech environment of immune system stimulation, where funding inflows depend on test results and FDA Fast Track designations accelerate time-to-market. The company is developing immune modulation methods to combat sepsis and allergies. Total assets amount to 15.98. The stock's price history confirms that the sector remains stable despite risks of supply chain disruptions and complexities regarding foreign patents.

Total assets, reverse-calculated via ROA as the sum of equity and liabilities, determine the aggregate resource potential of Revelation Biosciences (REVB), which currently stands at 15.98. Analyzing the dynamics of assets (equity + liabilities) allows for an assessment of the company's financial stability during clinical trials, a period when proprietary protection of immunomodulators and FDA regulatory barriers drive the long-term business value.